These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29140883)

  • 1. MAGE-A4 and MAGE-A1 Immunohistochemical Expression in High-grade Endometrial Cancer.
    Srdelić S; Kuzmić-Prusac I; Spagnoli GC; Juretić A; Čapkun V
    Int J Gynecol Pathol; 2019 Jan; 38(1):59-65. PubMed ID: 29140883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray.
    Chitale DA; Jungbluth AA; Marshall DS; Leitao MM; Hedvat CV; Kolb D; Spagnoli GC; Iversen K; Soslow RA
    Mod Pathol; 2005 Jan; 18(1):119-26. PubMed ID: 15272278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
    Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
    Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
    Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
    Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
    Reid-Nicholson M; Iyengar P; Hummer AJ; Linkov I; Asher M; Soslow RA
    Mod Pathol; 2006 Aug; 19(8):1091-100. PubMed ID: 16648864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer.
    Tunuguntla R; Ripley D; Sang QX; Chegini N
    Gynecol Oncol; 2003 Jun; 89(3):453-9. PubMed ID: 12798711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of lymphovascular space invasion and nodal involvement in intermediate- and high-risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy.
    Narayan K; Khaw P; Bernshaw D; Mileshkin L; Kondalsamy-Chennakesavan S
    Int J Gynecol Cancer; 2012 Feb; 22(2):260-6. PubMed ID: 22080878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
    Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
    Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
    Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
    Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
    Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
    Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
    Fadare O; Parkash V
    Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas.
    Resnick MB; Sabo E; Kondratev S; Kerner H; Spagnoli GC; Yakirevich E
    Int J Cancer; 2002 Sep; 101(2):190-5. PubMed ID: 12209997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
    Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
    Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
    Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
    Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
    Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
    Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
    Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
    Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.